Gemcitabine - Accord Healthcare
Alternative Names: Gemcitabine hydrochloride - Accord HealthcareLatest Information Update: 14 Jan 2022
At a glance
- Originator Accord Healthcare
- Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- Phase III Bladder cancer
Most Recent Events
- 29 Oct 2020 Phase-III clinical trials in Bladder cancer (Recurrent) in Sweden (IV) (EudraCT2020-001728-33)
- 15 Jan 2018 Gemcitabine is still not yet launched for Breast cancer, Non-small cell lung cancer, Ovarian cancer, and Pancreatic cancer in USA (IV) (Literature review)
- 17 Aug 2017 Chemical structure information added